EE05214B1 - Polool-IFN- β konjugaat, selle valmistamismeetod ja farmatseutiline kompositsioon - Google Patents

Polool-IFN- β konjugaat, selle valmistamismeetod ja farmatseutiline kompositsioon

Info

Publication number
EE05214B1
EE05214B1 EEP200000614A EEP200000614A EE05214B1 EE 05214 B1 EE05214 B1 EE 05214B1 EE P200000614 A EEP200000614 A EE P200000614A EE P200000614 A EEP200000614 A EE P200000614A EE 05214 B1 EE05214 B1 EE 05214B1
Authority
EE
Estonia
Prior art keywords
ifn
polyol
conjugate
preparation
pharmaceutical composition
Prior art date
Application number
EEP200000614A
Other languages
English (en)
Estonian (et)
Inventor
El Tayar Nabil
J. Roberts Michael
Harris Milton
Sawlivich Wayne
Original Assignee
Applied Research Systems Ars Holding N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems Ars Holding N.V. filed Critical Applied Research Systems Ars Holding N.V.
Publication of EE200000614A publication Critical patent/EE200000614A/xx
Publication of EE05214B1 publication Critical patent/EE05214B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurosurgery (AREA)
  • AIDS & HIV (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EEP200000614A 1998-04-28 1999-04-28 Polool-IFN- β konjugaat, selle valmistamismeetod ja farmatseutiline kompositsioon EE05214B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8333998P 1998-04-28 1998-04-28
PCT/US1999/009161 WO1999055377A2 (fr) 1998-04-28 1999-04-28 Conjugues de polyol-ifn beta

Publications (2)

Publication Number Publication Date
EE200000614A EE200000614A (et) 2002-04-15
EE05214B1 true EE05214B1 (et) 2009-10-15

Family

ID=22177687

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000614A EE05214B1 (et) 1998-04-28 1999-04-28 Polool-IFN- β konjugaat, selle valmistamismeetod ja farmatseutiline kompositsioon

Country Status (31)

Country Link
US (3) US6638500B1 (fr)
EP (2) EP1421956B1 (fr)
JP (2) JP4574007B2 (fr)
KR (1) KR100622796B1 (fr)
CN (2) CN100335503C (fr)
AR (1) AR020070A1 (fr)
AT (2) ATE275422T1 (fr)
AU (1) AU762621B2 (fr)
BG (2) BG65046B1 (fr)
BR (1) BR9910023A (fr)
CA (2) CA2565375A1 (fr)
CY (1) CY1108022T1 (fr)
CZ (2) CZ298579B6 (fr)
DE (2) DE69936409T2 (fr)
DK (2) DK1421956T3 (fr)
EA (2) EA003789B1 (fr)
EE (1) EE05214B1 (fr)
ES (2) ES2285286T3 (fr)
HK (2) HK1038194A1 (fr)
HU (1) HUP0300548A3 (fr)
IL (1) IL139286A (fr)
NO (2) NO329749B1 (fr)
NZ (1) NZ507456A (fr)
PL (2) PL193352B1 (fr)
PT (2) PT1421956E (fr)
SI (2) SI1421956T1 (fr)
SK (2) SK286654B6 (fr)
TR (2) TR200101751T2 (fr)
TW (2) TWI266800B (fr)
UA (2) UA79430C2 (fr)
WO (1) WO1999055377A2 (fr)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
IL121860A0 (en) 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
US7220717B2 (en) 1997-08-14 2007-05-22 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use
US7704944B2 (en) 1997-08-14 2010-04-27 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis
PL200586B1 (pl) * 1998-10-16 2009-01-30 Biogen Idec Inc Polipeptydy zawierające mutanty interferonu-beta-1a, kodujące je cząsteczki kwasów nukleinowych, komórki gospodarza transformowane tymi cząsteczkami, sposób wytwarzania polipeptydów, zawierające je kompozycje farmaceutyczne i zastosowania polipeptydów
CZ299164B6 (cs) * 1998-10-16 2008-05-07 Biogen Idec Ma Inc. Farmaceutická kompozice obsahující glykosylovaný interferon-beta-1a navázaný na polymer
US7238368B2 (en) * 1999-04-23 2007-07-03 Alza Corporation Releasable linkage and compositions containing same
JP4558952B2 (ja) * 1999-04-23 2010-10-06 アルザ コーポレイション リポソームにおいての使用のための開裂可能な結合を有する複合体
US7303760B2 (en) * 1999-04-23 2007-12-04 Alza Corporation Method for treating multi-drug resistant tumors
US7144574B2 (en) 1999-08-27 2006-12-05 Maxygen Aps Interferon β variants and conjugates
US7431921B2 (en) 2000-04-14 2008-10-07 Maxygen Aps Interferon beta-like molecules
US6531122B1 (en) 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
TR200101086A3 (fr) * 1999-10-15 2001-08-21
JP4593048B2 (ja) 1999-12-24 2010-12-08 協和発酵キリン株式会社 分岐型ポリアルキレングリコール類
MXPA02006795A (es) 2000-01-10 2005-04-19 Maxygen Holdings Ltd Conjugados g-csf.
IL150692A0 (en) 2000-02-11 2003-02-12 Maxygen Aps FACTOR VII OR VIIa-LIKE MOLECULES
WO2002060978A1 (fr) 2001-01-30 2002-08-08 Kyowa Hakko Kogyo Co., Ltd. Polyalkylene glycols ramifies
EP1234583A1 (fr) 2001-02-23 2002-08-28 F. Hoffmann-La Roche Ag Conjugués du PEG et du HGF-NK4
CA2469846A1 (fr) 2001-02-27 2002-09-26 Maxygen Aps Nouvelles molecules de type interferon beta
JP4444652B2 (ja) 2001-07-11 2010-03-31 マキシゲン・ホールディングズ・リミテッド Ｇ−ｃｓｆ結合体
DK3025726T3 (da) 2002-01-18 2019-12-09 Biogen Ma Inc Polyalkylenpolymerforbindelser og anvendelser deraf
TWI334785B (en) 2002-06-03 2010-12-21 Serono Lab Use of recombinant ifn-β1a and pharmaceutical composition comprising recombinant ifn-β1a for the treatment of hcv infection in patients of asian race
WO2004020468A2 (fr) * 2002-08-28 2004-03-11 Maxygen Aps Molecules d'interferon de type $g(b) pour le traitement du cancer
US8129330B2 (en) * 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
BR0317752A (pt) * 2002-12-26 2005-11-22 Mountain View Pharmaceuticals Conjugados poliméricos de citocinas, quimiocinas, fatores do crescimento, hormÈnios polipeptìdicos e seus antagonistas com atividade de ligação a receptores conservada
RS20050502A (en) 2002-12-26 2007-08-03 Mountain View Pharmaceuticals Inc., Polymer conjugates of interferon- beta with enhanced biological potency
CA2519873C (fr) 2003-03-20 2012-12-18 Maxygen Holdings Ltd. Variants de fvii ou fviia
TWI272948B (en) 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
GB0316294D0 (en) * 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
EP2633866A3 (fr) 2003-10-17 2013-12-18 Novo Nordisk A/S Thérapie combinée
MXPA06008507A (es) * 2004-02-02 2008-02-13 Ambrx Inc Cuatro polipeptidos en haz helicoidal humanos modificados y sus usos.
AU2008201682B2 (en) * 2004-02-02 2011-02-24 Ambrx, Inc. Modified human interferon polypeptides and their uses
EP1586334A1 (fr) * 2004-04-15 2005-10-19 TRASTEC scpa G-CSF conjugés avec PEG
ZA200609412B (en) 2004-05-17 2008-07-30 Ares Trading Sa Hydrogel interferon formulations
ATE543506T1 (de) 2004-06-01 2012-02-15 Ares Trading Sa Methode zur stabilisierung von proteinen
US7731948B2 (en) 2004-06-01 2010-06-08 Ares Trading S.A. Stabilized interferon liquid formulations
TW200633718A (en) * 2004-12-16 2006-10-01 Applied Research Systems Treatment of hepatitis c in the asian population
US7851565B2 (en) * 2004-12-21 2010-12-14 Nektar Therapeutics Stabilized polymeric thiol reagents
AU2005323106B2 (en) 2004-12-22 2010-07-29 Ambrx, Inc. Methods for expression and purification of recombinant human growth hormone
CN103690936A (zh) 2004-12-22 2014-04-02 Ambrx公司 经修饰的人类生长激素
WO2006071840A2 (fr) * 2004-12-22 2006-07-06 Ambrx, Inc. Formulations d'hormone de croissance humaine comportant un acide amine code de maniere non naturelle
WO2006134173A2 (fr) 2005-06-17 2006-12-21 Novo Nordisk Health Care Ag Reduction et derivation selectives de proteines conçues par le genie genetique comprenant au moins une cysteine non native
CN101257926A (zh) * 2005-08-04 2008-09-03 尼克塔治疗亚拉巴马公司 G-csf部分与聚合物的轭合物
DK1917276T3 (en) 2005-08-26 2018-05-07 Ares Trading Sa Process for Preparation of Glycosylated Interferon Beta
ZA200801923B (en) 2005-09-01 2009-09-30 Ares Trading Sa Treatment of optic neuritis
US20070238656A1 (en) * 2006-04-10 2007-10-11 Eastman Kodak Company Functionalized poly(ethylene glycol)
EP2018437A2 (fr) * 2006-05-02 2009-01-28 Allozyne, Inc. Molécules substituées par des acides aminés
US20080096819A1 (en) * 2006-05-02 2008-04-24 Allozyne, Inc. Amino acid substituted molecules
EA020805B1 (ru) 2006-05-24 2015-01-30 Мерк Сероно С.А. Применение комбинации кладрибина и бета-интерферона для лечения рассеянного склероза
KR20090013816A (ko) 2006-05-24 2009-02-05 노보 노르디스크 헬스 케어 악티엔게젤샤프트 연장된 생체내 반감기를 갖는 인자 ⅸ 유사체
BRPI0810622A2 (pt) * 2007-05-02 2020-10-13 Ambrx, Inc. polipeptídeos de interferon beta modificados e seus usos
CA2707840A1 (fr) 2007-08-20 2009-02-26 Allozyne, Inc. Molecules substituees par des acides amines
SI2234645T1 (sl) * 2007-12-20 2012-07-31 Merck Serono Sa Formulacije peg interferon beta
MX344166B (es) 2008-02-08 2016-12-07 Ambrx Inc Leptina-polipeptidos modificados y sus usos.
CN101525381B (zh) * 2008-03-04 2012-04-18 北京百川飞虹生物科技有限公司 一种重组复合干扰素及其表达载体的构建和表达
US20100112660A1 (en) * 2008-05-30 2010-05-06 Barofold, Inc. Method for Derivatization of Proteins Using Hydrostatic Pressure
US20110124614A1 (en) * 2008-10-25 2011-05-26 Halina Offner Methods And Compositions For The Treatment of Autoimmune Disorders
DE102009032179A1 (de) * 2009-07-07 2011-01-13 Biogenerix Ag Verfahren zur Reinigung von Interferon beta
ES2365343B1 (es) 2009-11-19 2012-07-10 Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii Uso de cd98 como marcador de receptividad endometrial.
CN105524164A (zh) 2010-02-16 2016-04-27 诺沃—诺迪斯克有限公司 具有降低的vwf结合的因子viii分子
AR080993A1 (es) 2010-04-02 2012-05-30 Hanmi Holdings Co Ltd Formulacion de accion prolongada de interferon beta donde se usa un fragmento de inmunoglobulina
JP2013528374A (ja) 2010-05-10 2013-07-11 パーシード セラピューティクス リミテッド ライアビリティ カンパニー Ｖｌａ４のポリペプチド阻害剤
EP2593130A2 (fr) 2010-07-15 2013-05-22 Novo Nordisk A/S Variants stabilisés du factor viii
EP3466968A1 (fr) 2010-09-15 2019-04-10 Stichting Sanquin Bloedvoorziening Variantes de facteur viii dotées d'un apport cellulaire réduit
JP2014506889A (ja) * 2011-02-18 2014-03-20 ステムディーアール インク． Ｓｉｒｔ１発現誘導物質を含む敗血症または敗血症性ショックの予防または治療用組成物
KR20140054009A (ko) 2011-07-01 2014-05-08 바이엘 인텔렉쳐 프로퍼티 게엠베하 릴랙신 융합 폴리펩타이드 및 그의 용도
KR101979045B1 (ko) * 2011-10-01 2019-05-15 가부시키가이샤 도우사 고가쿠 겐큐쇼 당쇄 부가 폴리펩티드 및 상기 폴리펩티드를 포함하는 의약 조성물
WO2013130683A2 (fr) 2012-02-27 2013-09-06 Amunix Operating Inc. Compositions de conjugués xten et leurs procédés de préparation
MX2014010209A (es) 2012-02-29 2014-11-21 Toray Industries Agente inhibidor para acumulacion de fluido de la cavidad corporal.
SG11201507769SA (en) 2013-03-29 2015-10-29 Glytech Inc Polypeptide having sialylated sugar chains attached thereto
US11759500B2 (en) 2014-07-24 2023-09-19 Abion Inc. PEGylated interferon-beta variant
WO2016013697A1 (fr) * 2014-07-24 2016-01-28 에이비온 주식회사 Variant d'interféron bêta complexé à une molécule de polyéthylène glycol
MX2017002140A (es) 2014-08-19 2017-08-21 Biogen Ma Inc Metodo de pegilacion.
AU2016257724B2 (en) 2015-05-01 2021-02-25 Allysta Pharmaceuticals, Inc. Adiponectin peptidomimetics for treating ocular disorders
CA2989637C (fr) * 2015-06-19 2023-01-10 Eisai R&D Management Co., Ltd. Immunoglobulines conjuguees cys80
US11324811B2 (en) * 2017-04-17 2022-05-10 The Regents Of The University Of Colorado, A Body Corporate Optimization of enzyme replacement therapy for treatment of homocystinuria
WO2020158691A1 (fr) 2019-01-28 2020-08-06 東レ株式会社 Corps modifié de polyéthylène glycol pour facteur de croissance des hépatocytes ou fragment actif associé
CN113382775A (zh) 2019-01-28 2021-09-10 东丽株式会社 肝细胞生长因子或其活性片段的聚乙二醇修饰物

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5206344A (en) * 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
EP0229108B1 (fr) * 1985-06-26 1990-12-27 Cetus Corporation Solubilisation de proteines pour des compositions pharmaceutiques utilisant une conjugaison de polymeres
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US5208344A (en) * 1987-07-31 1993-05-04 American Home Products Corporation Naphthalenepropionic acid derivatives as anti-inflammatory/antiallergic agents
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
PT730470E (pt) 1993-11-10 2002-08-30 Enzon Inc Conjugados melhorados de interferao-polimero
CA2167090C (fr) 1994-03-31 2002-05-14 Timothy D. Bartley Compositions et methodes de stimulation de la croissance et de la differentiation des megacaryocytes
NZ285664A (en) * 1994-05-18 1998-07-28 Inhale Therapeutic Syst Dry powder interferon composition adapted for pulmonary delivery
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
KR0176625B1 (ko) 1996-11-05 1999-04-01 삼성전자주식회사 적외선 물체검출장치
ATE200030T1 (de) * 1997-01-29 2001-04-15 Polymasc Pharmaceuticals Plc Pegylationsverfahren
NZ502375A (en) * 1997-07-14 2001-11-30 Bolder Biotechnology Inc The addition of non-natural cysteine derivatives to cause the protein to act as antagonists of the GH family
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
US6531122B1 (en) * 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates

Also Published As

Publication number Publication date
NZ507456A (en) 2003-10-31
DE69920002D1 (de) 2004-10-14
CZ20003995A3 (en) 2001-06-13
CN1187094C (zh) 2005-02-02
NO329749B1 (no) 2010-12-13
TWI232882B (en) 2005-05-21
EP1421956B1 (fr) 2007-06-27
UA66857C2 (uk) 2004-06-15
EE200000614A (et) 2002-04-15
HUP0300548A3 (en) 2005-07-28
EA005495B1 (ru) 2005-02-24
SK286217B6 (sk) 2008-05-06
ATE365563T1 (de) 2007-07-15
TWI266800B (en) 2006-11-21
IL139286A (en) 2005-12-18
PL344490A1 (en) 2001-11-05
EA003789B1 (ru) 2003-10-30
ES2224649T3 (es) 2005-03-01
JP2010184929A (ja) 2010-08-26
HK1038194A1 (en) 2002-03-08
US6638500B1 (en) 2003-10-28
KR100622796B1 (ko) 2006-09-13
BG104871A (en) 2001-07-31
WO1999055377A2 (fr) 1999-11-04
US20040043002A1 (en) 2004-03-04
JP2002512983A (ja) 2002-05-08
CN100335503C (zh) 2007-09-05
EA200001111A1 (ru) 2001-04-23
CA2330451A1 (fr) 1999-11-04
KR20010071158A (ko) 2001-07-28
SK16222000A3 (sk) 2001-04-09
SK286654B6 (sk) 2009-03-05
ES2285286T3 (es) 2007-11-16
NO332224B1 (no) 2012-07-30
NO20005337L (no) 2000-12-28
PL193352B1 (pl) 2007-02-28
CY1108022T1 (el) 2013-09-04
WO1999055377A9 (fr) 2000-03-02
ATE275422T1 (de) 2004-09-15
PT1075281E (pt) 2004-11-30
UA79430C2 (en) 2007-06-25
DE69936409D1 (de) 2007-08-09
WO1999055377A3 (fr) 1999-12-29
EP1075281B1 (fr) 2004-09-08
EP1421956A1 (fr) 2004-05-26
BG65046B1 (bg) 2007-01-31
PT1421956E (pt) 2007-07-13
BR9910023A (pt) 2000-12-26
US20070141620A1 (en) 2007-06-21
EP1075281A2 (fr) 2001-02-14
AR020070A1 (es) 2002-04-10
BG109291A (en) 2006-04-28
AU762621B2 (en) 2003-07-03
SI1075281T1 (en) 2005-02-28
US7700314B2 (en) 2010-04-20
DE69936409T2 (de) 2008-04-17
HUP0300548A2 (hu) 2003-06-28
NO20005337D0 (no) 2000-10-23
NO20100324L (no) 2000-12-28
CZ298579B6 (cs) 2007-11-14
TR200101751T2 (tr) 2002-05-21
SI1421956T1 (sl) 2007-10-31
CN1637020A (zh) 2005-07-13
TR200003161T2 (tr) 2001-01-22
DK1075281T3 (da) 2005-01-03
US7357925B2 (en) 2008-04-15
BG64694B1 (bg) 2005-12-30
PL196533B1 (pl) 2008-01-31
AU3767499A (en) 1999-11-16
IL139286A0 (en) 2001-11-25
HK1076115A1 (en) 2006-01-06
EA200300382A1 (ru) 2005-02-24
DK1421956T3 (da) 2007-10-01
CZ298597B6 (cs) 2007-11-21
JP4574007B2 (ja) 2010-11-04
CN1302209A (zh) 2001-07-04
DE69920002T2 (de) 2005-09-22
CA2565375A1 (fr) 1999-11-04

Similar Documents

Publication Publication Date Title
EE05214B1 (et) Polool-IFN- β konjugaat, selle valmistamismeetod ja farmatseutiline kompositsioon
EE200000596A (et) Tienüülasolüülalkoksüetaanamiinderivaadid, nende ja nende soolade valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja kasutamine ning vaheühend ja selle valmistamismeetod
EE200100684A (et) Indalüülasendatud benseenkarboksamiidid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid
EE03338B1 (et) Tromboosivastane ravim, selle valmistamise protsess ja kasutamine
EE04275B1 (et) Kinoliini derivaadid, nende valmistamismeetodid, kasutamine ja farmatseutilised kompositsioonid
EE200100431A (et) 16-halogenoepotilooni derivaadid, nende valmistamismeetod ja farmatseutiline kasutamine
EE200200487A (et) Asetidiini derivaadid, nende valmistamismeetodid ja farmatseutiline kompositsioon
EE200100033A (et) Enterokattega ravimkoostis ja selle valmistamise meetod
EE04926B1 (et) Enterokattega ravimkoostis ja selle valmistamise meetod
EE9500064A (et) Asendatud 1H-imidasoolid, nende valmistamismeetodid ja farmatseutilised kompositsioonid
EE200200095A (et) Sulfonüülkarboksamiidi derivaadid, nende kasutamine, ravim ja nende valmistamismeetod
EE200100252A (et) Pürimidiinderivaadid, nende valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja sellevalmistamismeetod, kombinatsioon ning saadus
EE03594B1 (et) Depooravimiks sobiv farmatseutiline kompositsioon, selle valmistamismeetod ja kasutamine
EE04721B1 (et) Fenüülksantiini derivaadid, nende valmistamismeetodid ja kasutamine
EE200000225A (et) Arüüloksüalküüldialküülamiinid, nende valmistamismeetodid ja farmatseutiline kompositsioon
EE9800302A (et) Arüülglütsiinamiidi derivaadid, nende valmistamismeetod ja kasutamine ning farmatseutiline preparaat
EE9900112A (et) 2-tsüanoiminoimidasooli derivaadid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid
EE9800200A (et) Bensoüülguanidiini derivaadid, nende valmistamismeetod, kasutamine ja farmatseutiline kompositsioon
EE200000767A (et) Asendatud triasolopüridasiini derivaat, selle valmistamismeetod ja kasutamine ning farmatseutiline kompositsioon
EE200100314A (et) Meetod farmatseutilise kompositsiooni valmistamiseks, farmatseutiline kompositsioon ja selle kasutamine
EE04119B1 (et) Külmkuivatamiseks sobiv ravimkoostis ja selle valmistamise meetod
EE04346B1 (et) Asoolid, nende valmistamismeetod, kasutamine ja farmatseutiline kompositsioon
EE04902B1 (et) Mikrograanul, selle valmistamismeetod ja farmatseutiline preparaat
EE03691B1 (et) 1,2,3,4-tetrahüdrobensofuro[3,4-c]püridiini derivaadid, nende valmistamismeetod, kasutamine, farmatseutiline kompositsioon ja selle valmistamismeetod
EE200100209A (et) Tritsüklilised 3-piperidiinid, nende valmistamismeetod, kasutamine, farmatseutiline kompositsioon ja selle valmistamismeetod

Legal Events

Date Code Title Description
GB1A Change in the ownership or in the address of the owner
KB4A Valid patent at the end of a year

Effective date: 20101231

HC1A Change of owner name
MM4A Lapsed by not paying the annual fees

Effective date: 20130428